All In Biotech

Drug Trial Radar · NCT03686124

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

375

Planned (sponsor's estimate)

Start

May 14, 2019

Primary completion

Dec 2028

Study completion Jun 2032

Sponsor

Lead sponsor
Immatics US, Inc.Industry
Sponsor type
Industry
First posted
Sep 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

Conditions

  • Refractory Cancer
  • Recurrent Cancer
  • Solid Tumor, Adult
  • Cancer

Interventions

  • IMA203 ProductBiological

    The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

  • IMA203 product- flat doseBiological

    The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells

  • IMA203CD8 ProductBiological

    The cell dose will be based on viable CD3+CD8+ HLA- Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula

  • NivolumabDrug

    Nivolumab will be given post IMA203/IMA203CD8 infusion, after hematologic recovery is achieved. Clinical supply provided by Bristol Myers Squibb.

  • IMADetect®Device

    IMADetect® is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in Immatics clinical trials.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Determine the MTD and/or recommended dose for extension for IMA203/IMA203CD8Time frame: 28 days
  2. Phase 1 and Phase 2: Number and grade of treatment emergent adverse events and adverse events of special interest in subjects treated.Time frame: 35 days
  3. Phase 1 and Phase 2: Tumor ResponseTime frame: 5 years

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Stanford Cancer Institute

    Stanford, California · Recruiting

  • University of Colorado, Anschutz Medical Campus

    Aurora, Colorado · Recruiting

  • University of Miami Hospital and Clinics

    Miami, Florida · Recruiting

  • University of Chicago Medical Center

    Chicago, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run

    Columbus, Ohio · Recruiting

  • University of Pennsylvania, Perelamn Center for Advanced Medicine

    Philadelphia, Pennsylvania · Recruiting

  • Thomas Jefferson University, Honickman Center

    Philadelphia, Pennsylvania · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie

    Berlin, Germany · Recruiting

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Universitätsklinikum Heidelberg, Nationales Centrum für Tumorerkrankungen (NCT)

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • Klinikum rechts der Isar der Technischen Universität München

    Munich, Bavaria, Germany · Recruiting

  • Universitätsklinikum Würzburg

    Würzburg, Bavaria, Germany · Recruiting

  • Universitätsklinikum Bonn - Medizinische Klinik III

    Bonn, North Rhine-Westphalia, Germany · Recruiting

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz

    Mainz, Rhineland-Palatinate, Germany · Recruiting

  • Universitätsklinikum C.-G.-Carus Dresden

    Dresden, Saxony, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.